These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22420065)

  • 1. Controlled substances and List I chemical registration and reregistration fees. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2012 Mar; 77(51):15234-50. PubMed ID: 22420065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Registration and reregistration application fees. Confirmation of final rule, remanded for further notice and comment, and response to comments.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2002 Aug; 67(154):51987-52007. PubMed ID: 12194173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of a chemical precursor used in the illicit manufacture of fentanyl as a List I chemical. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2008 Jul; 73(144):43355-7. PubMed ID: 18949877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Registration and reregistration application fees. Final rule; remanded for further notice and comment.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 1996 Dec; 61(251):68624-6. PubMed ID: 12192680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schedule of controlled substances; placement of fospropofol into schedule IV. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2009 Oct; 74(192):51234-6. PubMed ID: 19877370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Removal of thresholds for the List I chemicals pseudoephedrine and phenylpropanolamine. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2010 Jul; 75(129):38915-22. PubMed ID: 20608288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schedules of controlled substances: placement of lisdexamfetamine into schedule II. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2007 May; 72(85):24532-4. PubMed ID: 17520775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schedules of controlled substances: placement of 5-methoxy-N,N-dimethyltryptamine into Schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2010 Dec; 75(243):79296-300. PubMed ID: 21171485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schedules of controlled substances: placement of Zopiclone into schedule IV. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2005 Apr; 70(63):16935-7. PubMed ID: 15806735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schedules of controlled substances: placement of lacosamide into schedule V. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2009 May; 74(97):23789-90. PubMed ID: 19507328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schedule of controlled substances: placement of dichloralphenazone into Schedule IV. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2001 Aug; 66(159):42943-4. PubMed ID: 11794309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Authorized sources of narcotic raw materials. Final rule.
    Fed Regist; 2008 Feb; 73(25):6843-51. PubMed ID: 18389916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2005 Jul; 70(144):43633-5. PubMed ID: 16050051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Registration requirements for importers and manufacturers of prescription drug products containing ephedrine, pseudoephedrine, or phenylpropanolamine. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2010 Feb; 75(20):4973-82. PubMed ID: 20352663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schedules of controlled substances: placement of tapentadol into schedule II. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2009 May; 74(97):23790-3. PubMed ID: 19507329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of red phosphorus, white phosphorus and hypophosphorous acid (and its salts) as list I chemicals; exclusions and waivers. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2003 Jun; 68(121):37411-4. PubMed ID: 12836650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of exemptions for chemical mixtures containing the list I chemicals ephedrine and/or pseudoephedrine. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2008 Jul; 73(133):39611-4. PubMed ID: 18850676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exemption from import/export requirements for personal medical use. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2004 Sep; 69(177):55343-7. PubMed ID: 15366181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. Interim final rule with request for comments.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2009 Apr; 74(64):15595-625. PubMed ID: 19507319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of the Comprehensive Methamphetamine Control Act of 1996; regulation of pseudoephedrine, phenylpropanolamine, and combination ephedrine drug products and reports of certain transactions to nonregulated persons. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2002 Mar; 67(60):14853-62. PubMed ID: 11922057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.